Bipolar Depression Case Series-The Art and Science of Clinical Management: Treatment Choices and Monitoring Change
neuroscienceCME Webcast
Premiere Date: Thursday, February 5, 2015This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, February 5, 2016
Note: Credit Is No Longer Available
 | Charles B. Nemeroff, MD, PhD Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX |
 | Terence A. Ketter, MD Professor of Psychiatry and Behavioral Sciences Founder and Chief, Bipolar Disorders Clinic Stanford University School of Medicine Stanford, CA |
 | Natalie L. Rasgon, MD, PhD Professor, Psychiatry and Behavioral Sciences, and by courtesy, Obstetrics and Gynecology Director, Center for Neuroscience in Women's Health Stanford University School of Medicine Stanford, CA |
Bipolar disorder is one of the world’s 10 most disabling conditions, taking away years of healthy functioning from individuals who have the illness. According to Judd and colleagues, individuals with bipolar disorder spend most of their time in a symptomatic, depressed phase. In fact, a significantly greater percentage of time is spent in a depressed mood than in mania, hypomania, or euthymia.1 Individuals with bipolar disorder are at high risk for comorbid medical disorders such as metabolic or cardiovascular disorders, and unfortunately, several of the psychotropic medications that are used to treat bipolar disorder may increase the risk of developing certain medical illnesses. Careful, ongoing assessment, monitoring and allows for individualized treatment-selection that can help reduce some of the treatment-related risk factors and improve quality of life for these patients.2
On December 15, 2014, a neuroscienceCME Live and On Demand featured series of cases on bipolar depression. To meet the learning preferences of busy clinicians, the activity has been divided into three short modules, each featuring a patient case that demonstrates the complex challenges of presented by patients with bipolar depression
Module 1: Treatment Choices and Monitoring Change Click here to begin this activity now
Module 2: Adjusting and Monitoring Treatment Toward Remission Click here to access this activity
Module 3: Balancing Efficacy and Safety Click here to access this activity
Each module is certified for .5 AMA PRA Category 1 Credit™. We encourage participants to complete all three modules to optimize the learning experience and to gain valuable insights for treating their patients with bipolar depression.
- Judd LL, et al. J Affect Disord. 2003;73(1-2):19-32. PMID: 12507734.
- McIntyre RS, et al. Ann Clin Psychiatry. 2012;24(2):163-169. PMID: 22563572.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this initiative is:
Monitor patients with bipolar depression at least every three months for metabolic changes.
At the end of this CE activity, participants should be able to:
- Utilize evidence-based measurement tools for assessment and monitoring of treatment for patients with bipolar depression.
Supported by an educational grant from Sunovion Pharmaceuticals Inc.
Physicians, physician assistants, nurse practitioners, pharmacists, and other health care professionals with an interest in bipolar depression.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number:
0376-0000-15-006-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST1978 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Allergen, Inc.; Eli Lilly and Company; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals; SK Pharma; Roche; Shire Pharmaceuticals; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma; National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost; Xhale, Inc.; and Skyland Trail. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; NovaDel Pharma, Inc. (2011); and Skyland Trail. He is a stockholder of AbbVie Inc,; Celgene Corporation; CeNeRx BioPharma; PharmaNeuroBoost; Reevax Pharmaceuticals LLC; Seattle Genetics, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; BioPharma; CeNeRx NovaDel Pharma, Inc.; Pharmaneuroboost; Revaax Pharmaceuticals LLC; and Xhale, Inc. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Dr. Ketter has received grant/research support from the Agency for Healthcare Research (AHRQ) and Sunovion Pharmaceuticals, Inc. He serves as a consultant for Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Prophase, LLC; Sunovion Pharmaceuticals, Inc.; andTeva Pharmaceuticals. He has received lecture honoraria from Pfizer Inc. His spouse (Nzeera Ketter, MD) is an employee of Janssen Pharmaceuticals and holds stock from Janssen Pharmaceuticals.
Dr. Rasgon has disclosed that she has received grant support from the American Diabetes Association; Corcept Pharmaceuticals; and Magceutics, Inc. She serves as a consultant for Shire Pharmaceuticals; Sunovion Pharmaceuticals, Inc.; and Takeda Pharmaceuticals, U.S.A., Inc.
Tony Graham, MD (content/peer reviewer) has no disclosures to report.
Ruth Cody, BSN, RN-BC (content/peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Sunovion Pharmaceuticals Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV1-079-020515-23
